To determine which parts of the cobalamin (cbl) 
Introduction
Cobalamin (cbl)' deficiency is a major cause ofreversible megaloblastic anemia and neurobehavioral abnormalities, such as myelopathy and dementia, in humans (1) . The pathophysiol- 1 . Abbreviations used in this paper: ado-cbl, adenosyl cobalamin; cbl, cobalamin; CN-cbl, cyano-cbl; CoA, coenzyme A; Me-cbl, methyl-cbl; N20, nitrous oxide; OH-cbl, hydroxy-cbl.
ogy underlying these demyelinating central nervous system lesions resulting from deficiency is not understood and has been hampered by the lack of convenient animal models. Lengthy periods (up to 3 yr) of dietary deprivation with prevention of copraphagia (2) , or inhaled nitrous oxide (N20) have been used in the past to produce the deficient state (3) .
Cbl is required by man and other animals as the co-factor for two enzymes: L-methylmalonyl-coenzyme A (CoA) mutase (EC-5.4.99.2) and methionine synthetase (tetrahydropteroylglutamate; L-homocysteine-S-methyltransferase EC 2.1.1.13). Valine, isoleucine, methionine, odd chain fatty acids and other compounds are metabolized to propionyl-CoA which is carboxylated to form D-methylmalonyl-CoA ( Fig. 1 A) , which is either hydrolyzed by D-methylmalonyl-CoA hydrolase to form methylmalonic acid and CoA (4) or racemized to L-methylmalonylCoA (5) which is the substrate for the adenosyl-cbl (ado-cbl) requiring enzyme L-methylmalonyl-CoA mutase (6) . The other cbl-dependent enzyme, shown in Fig. 1 B, is methionine synthetase which demethylates methyltetrahydrofolate as it methylates homocysteine to form methionine (7) .
Using newly developed sensitive and specific capillary gas chromatographic/mass spectrometric assays (8, 9) , we have shown that serum levels of methylmalonic acid and total homocysteine are markedly elevated in 95% of patients with clinically confirmed cbl deficiency and that the elevated levels fall promptly after cbl therapy is begun in deficient patients (10) (11) (12) . Thus, elevated levels of serum methylmalonic acid and total homocysteine can be used to confirm metabolic conditions of cbl deficiency or cbl-dependent enzyme inhibition.
Because cbl is synthesized only by bacteria and other prokaryotic organisms (13) , higher animals have developed mechanisms for the gastrointestinal absorption and plasma transport ofthis substance ( 14, 15) . In addition to synthesizing cbl, microorganisms synthesize cbl analogues which have bases as their nucleotide moieties other than 5, 6 dimethylbenzimidazole which is present in cbl (see Fig. 2 , Nos. 12-16). Previous investigations have shown that there are a variety of mechanisms which appear to prevent the absorption and tissue dissemination of certain of these cbl analogues (16) (17) (18) . Previous studies have also shown that there are cbl analogues ofunknown structure in human serum (19) , animal tissues (20) , and foodstuffs and vitamin supplements (21) , though their effects on cbl metabolism are largely unknown.
In addition to the naturally occurring cbl analogues, many cbl analogues have been synthesized with side chain modifications (22) . Many of these analogues have shown inhibitory effects against bacteria (23). However, the studies performed in the past of various analogues administered to higher animals have been disappointing (24) .
To determine which sections ofthe cbl molecule are important for in vivo activity, we synthesized 16 (16, 25) . The structural assignments of the monocarboxylic acids was followed as recommended by Anton et al. (26) .
Analogues with substitutions at the e-propionamide side chain of the C-ring were made by a modification of the methods of Armitage (27) (25) .
The naturally occurring cbl analogues with nucleotide moieties different than that in cbl were produced by bacterial fermentation by the method of Perlman and Barrett (29) . The following respective bases were added to cultures ofPropionibacterium arabinosum to obtain the following cbl analogues: benzimidazole, [ were purified from the bacteria by boiling in KCN containing buffer followed by affinity chromatography on hog non-IF Sepharose and separation by paper chromatography as described previously (30) .
All of the analogues were synthesized in their CN-form and were converted into their OH-(aquo)-form before administration to the rats by the method of Dolphin (31). The concentration of cbl and cbl analogues was determined spectrophotometrically at 367.5 nm in 0.1 M KCN. A molar extinction coefficient of 30,800 M-' cm-' was used for each analogue except for CN-cbl [13-epi] for which a value of 20, 600 MWcm- (16) was used. The final analogue solutions gave a single peak when they were analyzed for purity by HPLC utilizing separation methods previously described (25) .
Cbl analogue administration. To test the metabolic effects of the administration of cbl analogues to rats, eight experimental male Sprague-Dawley rats (300-400 g size) and eight simultaneous control rats were implanted subcutaneously with model 2002 osmotic minipumps (Alza Corp., Palo Alto, CA) which contained -1 mg OH-cbl analogue in H20 or H20 alone, respectively. The pumps released 2 Ag/h for 14 d (672 ,g total). In one experiment, pumps were replaced at 21 d and the animals were sacrificed after 42 d. Rats were sacrificed with ether, blood was immediately obtained by cardiac puncture, and the livers were immediately frozen in a dry ice acetone bath. For all of the analogue studies, the rats were housed in the University of Colorado Animal Resource Center and fed a standard cbl-containing lab chow obtained from various sources. Coprophagia was not prevented. Table I. placed in an air-tight Plexiglass box and exposed to 50% N20/50% 02 for 28 d as previously described (32) . Control rats were housed as above in the Animal Resource Center. Another control experiment with eight rats exposed to 50% NJ50% 02 was also performed. Fischer strain male weanling ( 15 g) rats were used for the cbl-deficient diet studies. The animals were placed in individual wire bottom metabolic cages and were fed an amino acid-based cbl-deficient diet or control diet, which was identical to the deficient diet except that it contained cbl (33). To determine the effects of OH-cbl [c-lactam] in the Fischer rat strain, the same method was used as described above in the Sprague-Dawley rats except that the control synthetic diet was fed to both experimental rats and controls, and the control pumps contained 0. 15 M saline.
Enzyme and metabolite assay methods. Frozen liver was homogenized in 2.5 vol of 0.028 M NaPO4, pH 7, and centrifuged at 30,000 g for I h. The supernatants were assayed for L-methylmalonyl-CoA mutase as previously described (34) . Assays were done without added adocbl (holo-L-methylmalonyl-CoA mutase) and with ado-cbl in the dark (total L-methylmalonyl-CoA mutase). Methionine synthetase was assayed in liver supernatants as previously described (7, 35) , both with and without CN-cbl in the assay. It is not clear whether the assays with and without cbl present represent the total and holo forms of this enzyme (7) . D-Methylmalonyl-CoA hydrolase and D,L-methylmalonylCoA racemase were assayed on liver supernatants as previously described (4, 5) . An enzyme unit (EU) refers to I tmol of substrate converted per minute.
Serum methylmalonic acid, succinic acid, total homocysteine, methionine, and total cysteine were assayed by capillary gas chromatography/mass spectrometry (GC/MS) utilizing tert-butyldimethylsilyl derivatives as previously described (8, 9) , using a stable isotope internal standard for each metabolite quantified. Dimer formation does not interfere with quantitation of homocysteine and cysteine with these methods because stable isotope containing internal standards are added to the samples before sample reduction and thus are randomized with endogenous homocysteine and cysteine throughout sample preparation and quantitation.
Serum and liver cbl and folate levels were determined using the holo-methylmalonyl-CoA mutase was physiologically significant as the mean serum levels of methylmalonic acid in the experimental animals (Fig. 4) were markedly increased to 3,200% of the values in control rats. The serum succinic acid levels were unchanged. The total liver L-methylmalonyl-CoA mutase activity (assayed with ado-cbl) increased to a mean of 152% as compared to the control (Fig. 3) . Fig. 5 shows that liver methionine synthetase activity was also decreased in the experimental animals who received OH-cbl[c-lactam]. When assayed without CN-cbl, the mean methionine synthetase activity was 43% of the mean control activity and when assayed with CNcbl, it was 18%. This suppression in methionine synthetase ac- . The data are expressed * as in Fig. 3 tivity appeared to be physiologically important because the mean serum total homocysteine level of the experimental rats was elevated to 341% ofthe mean control levels (Fig. 6 ). Serum methionine levels were not decreased and, in fact, were 118% ofthe mean control levels. Serum total cysteine levels were also unchanged (data not shown). At the end of the 42-d infusion, cbl levels in the liver were markedly decreased to 17% of control values, as shown in Fig. 7 . Liver folate levels were moderately decreased to 69% of the controls (Fig. 7) .
Comparison ofCbl and 17 Cbl analogues. Fig. 2 shows the structure ofcbl and ofthe 16 cbl analogues which were synthesized and then purified from cbl before administration to the rats. The number ofeach analogue in the figure corresponds to the number ofeach analogue in Table I and control rats as described in Fig. 3 (Table I ). In contrast, the addition of CN-cbl increased methionine synthetase activity in controls, rats infused with OH-cbl or inert analogues (Table I) . Similar findings (not presented in Table I Fig. 2 ), the C-ring modification, e-OH, demonstrated the most inhibition of cbl metabolism and was therefore used to make the series of substituted amides. The corresponding dimethyl- Table I ). Serum methionine levels were not significantly altered by cbl or any of the cbl analogues (data not presented).
The naturally occurring cbl analogues with nucleotide moieties different than that in cbl (compounds 13-16 in Fig. 2) showed little effect on either of the cbl-dependent enzymes with the exception of [BZAJOH-Cba which caused modest inhibition of both enzymes.
OH-cbl[ 1 3-epi] is an isomer ofOH-cbl with the only change being the position of the e-propionamide side chain in relation to the C-ring (Fig. 2, compound 10 would have been measured in the radiodilution assay as an Liver folate levels were moderately decreased in the aniextremely low "cbl" level due to its low affinity to the IF, but all mals who received the most potent cbl analogues to 69% ofthe of the OH-cblle-dimethylamide] would have been measured of [BZA]OH-Cba in the liver because it was detected by the N20-induced inhibition of Cbl metabolism. Table I shows radiodilution assay. Serum cbl levels were increased slightly in the data from rats who were exposed to 50% N20/50% 02 for the OH-cbl[c-lactamj and [c-lactone-]-treated animals, and either 1.5 or 28 d as compared to control rats. One experimenwere markedly increased in the animals infused with the anatal rat in the long-term exposure died of unknown causes durlogues with a high affinity to IF, i.e., compounds 3, 5, 6, 7, 8, ing the second week. As has been reported previously (32) , liver 1 1, and 13 in Table I. short exposure to N20, but mean liver methionine synthetase activity when assayed with CN-cbl showed a marked decrease to 16% of the mean control values with a corresponding increase in the serum total homocysteine to 549% of control. Serum methionine concentration decreased significantly to 78% of control levels. After 28 d ofN20 exposure, liver holo-Lmethylmalonyl-CoA mutase activity decreased to 55% of control with a corresponding increase in serum methylmalonic acid concentration to 2,190% ofcontrol levels. The liver methionine synthetase activity was decreased with an increase in serum total homocysteine concentration, similar to the data obtained after 1.5 d. The liver cbl level was markedly depleted to 36% of the mean control values in the long-term N20-treated rats. Liver folate levels were depleted to 43% of control after long-term exposure. Serum cbl was unchanged in the short-term exposed animals and decreased to 49% ofcontrol in the long-term-treated animals. D-Methylmalonyl-CoA hydrolase activity was significantly increased to 147% of the mean control values in the 50% 0250% N2 treated rats. An additional experiment with 50% 02/50% N2 exposure of rats for 28 d resulted in no changes in liver L-methylmalonyl-CoA mutase or methionine synthetase activity or serum methylmalonic acid and total homocysteine levels. Serum cbl and folate levels were significantly decreased to 55 and 63%, respectively, ofthe mean control values in the 50% 0J50% N2-treated rats.
Effects ofdietary Cbl deficiency. Table I also shows the results obtained in Fischer rats subjected to either a synthetic cbl-deficient diet with prevention of coprophagia (described in Methods) as compared to Fischer rats who were infused with OH-cbl[c-lactam] as described above for Sprague-Dawley rats.
After 168 d on the deficient diet, mean liver holo-L-methylmalonyl-CoA mutase in the experimental rats had decreased to 79% of control with a marked increase in serum methylmalonic acid concentration to 18,100% of control levels. Liver methionine synthetase when assayed with CN-cbl decreased to 53% and serum total homocysteine concentration was increased to 257%. Liver and serum cbl levels were decreased to 26 and [b-OH] (B-ring) did not result in inhibitors of cbl-dependent metabolism. The analogues with base modifications, i.e., the naturally occurring analogues, generally did not cause significant inhibition of the two enzymes with the possible exception of [BZA]OH-Cba. No analogue was found that increased the activity ofeither ofthe two enzymes when it was infused in rats, suggesting that the requirements for cbl as an active cofactor appear to be quite specific, and that rats cannot convert these analogues back to cbl. Even OH-cbl[ 1 3-epi] , an isomer of cbl, was inert.
Though the level of inhibition of holo-L-methylmalonylCoA mutase appeared modest when assayed in vitro in the liver supernatants (a maximum of 40% inhibition for OH-cbl[clactam]), the serum methylmalonic acid levels were markedly increased, ranging from 3-to -280-fold in the various experiments, demonstrating that the level of inhibition achieved caused a significant metabolic change in vivo. These serum levels of methylmalonic acid are comparable to levels seen in humans with symptomatic cbl deficiency (10) (11) (12) . The metabolic role or fate of methylmalonic acid is unknown at present, though we have shown in preliminary experiments that most (-85%) of a dose of (-'4C-methyl) methylmalonic acid is metabolized and only 15% is excreted in the urine (4) We have also shown that several cbl analogues with modifications ofthe B and C rings inhibit methionine synthetase activity to a degree similar to that found with N2O, a previously known inhibitor of methionine synthetase activity (32, 36) . Nitrous oxide has been shown to interact with reduced forms of cbl, resulting in rapid inactivation of methionine synthetase (36) . On prolonged exposure, nitrous oxide has been shown to cause the formation of cbl analogues and to deplete cbl (32) . When liver supernatants were assayed for methionine synthetase with CN-cbl in the incubation assay, a lower level ofactivity was detected than when the same supernatants were assayed without CN-cbl under the following conditions: (a) exposure to N20; (b) infusion with the inhibitory analogues ( Fig. 5 and Table I ); and (c) dietary deficiency. In contrast, in assays of liver supernatants from control rats or rats receiving inert analogues, the presence ofCN-cbl in the incubation increased methionine synthetase activity. Similar CN-cbl[c-lactam] in the depleted animals is also unknown. Regardless of the explanation for these phenomenon, the common practice of using the increase in methionine synthetase activity resulting from adding CN-cbl to enzyme assays as a measure of apo-enzyme cannot be accepted without further studies of the mechanism involved. 1428 The mechanism of inhibition of the cbl analogues is not known. However, it is possible that some ofthe analogues may displace cbl from the liver. Table I shows the percent ofbinding to hog IF as compared to cbl for the various analogues. Thus, for some analogues, the amount ofcbl measured in liver supernatants represents the sum of endogenous cbl and analogue if present. OH-cbl[c-lactam], which is measured only 0.1% as well as cbl, resulted in the marked displacement ofcbl from the liver because the measured mean total cbl in the experimentals was only 19% ofthe control value. Analogues which were measured in the IF assay (i.e., OH-cbl[e-dimethylamidel) also did not appear to accumulate in the liver because, in this case, the total cbl level had decreased to 56% of the control values. In contrast, when similar amounts of OH-cbl were infused, the mean liver cbl levels increased to 246% ofthe control animals. The inhibitory analogues also appeared to deplete the liver of folate. This is consistent with the hypothesis of the "methyl folate trap" (37) , wherein, because of the blocked activity of methionine synthetase, N5-methyltetrahydrofolate levels increase. It is then released from the cells and excreted in the urine resulting in eventual folate depletion of the organism.
There are many steps involved in cbl uptake, metabolism, and release from cells, and cbl analogues could act by inhibiting any of these steps. The analogues could act by actively inhibiting an enzyme or receptor or, if inert, by displacing cbl from the enzyme or receptor, or by stimulating the release of cbl from cells. Our data show that some of the inhibitory analogues displaced cbl and did not progressively accumulate in the liver. Because 80-90% ofliver cbl is bound to either methionine synthetase or L-methylmalonyl-CoA mutase, and there is no cbl storage form (38) , it appears that cbl had been therefore depleted from these two enzymes. However, the inhibition of steps in cbl metabolism before and after binding of the coenzyme forms to the two enzymes would decrease their cbl content as would direct competition of cbl and cbl analogue for actual binding to L-methylmalonyl-CoA mutase and methionine synthetase. In experiments with purified human apo methionine synthetase, every cbl analogue studied has been found to stimulate enzyme activity (Kolhouse, J. F., personal communication) rather than inhibit activity, in contrast to what was seen when the same analogues were infused in rats as described in the present experiments. Analogous experiments with coenzyme forms ofthe analogues have not yet been done with purified L-methylmalonyl-CoA mutase.
It is interesting that the naturally occurring analogues synthesized by bacteria are basically inert when infused in rats, demonstrating that which nucleotide moiety is present in the molecule is extremely important for the in vivo activity of cbl. Many ofthe analogues are present in large quantities in animal, and also presumably, human feces (39).
Though, the levels of serum methylmalonic acid and homocysteine achieved in the rats by the inhibitory analogues were similar to those in cbl-deficient humans the rats did not develop hematologic or neurologic abnormalities. This is not surprising because dietary deficiency (40) and exposure to N20 (41) produces megaloblastic anemia only in humans and neurologic abnormalities only in humans, monkeys, fruit bats, and possibly swine. The inhibitory analogues can now be used in the animal species susceptible to cbl deficiency to produce models of cbl deficiency. The analogues can also be used to induce models of methylmalonicaciduria (42) . The changes induced by the analogues were similar to those obtained with extensive periods of diet deficiency with prevention of copraphagia and N20 administration. The analogue infusions were more convenient, more economical, and in the case ofN20, much safer for laboratory personnel.
The analogues that have been shown to inhibit methionine synthetase activity in the present experiments might have potential as antiproliferative agents against human malignant cells. N20, which also decreases methionine synthetase activity, has already been shown to suppress the proliferation of malignant human hematopoietic cells in culture (43) and has been used to treat a few cases of human leukemia (44, 45) . It is also known to cause severe bone marrow suppression when humans are continuously exposed for more than a few days (46) . In vitro studies with cbl analogues and various cells grown in tissue culture are in progress.
